Safety, Biodistribution, and Dosimetry of FAP and Integrin α Dual-Targeting Radioligand Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas
1. 系统已在2026-09-28 10:32:47对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.2967/jnumed.126.272007
文献链接: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.126.272007
其他信息:
出版社: Society of Nuclear Medicine
作者: Jialin Xiang; Xuejun Wen; Rongxi Wang; Jiarou Wang; Xingtong Peng; Yanwei Wang; Naixin Liang; Dongyan Cao; Xiaoyuan Chen; Zhaohui Zhu; Jingjing Zhang

